The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta

Current Pharmaceutical Biotechnology

Volumn 12, Issue 5, 2011, Pages 715-730

  Stejskalova, Lucie ^a   Pavek, Petr ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Aryl hydrocarbon receptor; Aryl hydrocarbon receptor nuclear translocator; Cigarette smoke; CYP1A1; Cytochrome P450; Placenta; Pregnancy

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ARACHIDONIC ACID; AROMATIC AMINE; AROMATIC HYDROCARBON RECEPTOR; CAFFEINE; CARCINOGEN; CIGARETTE SMOKE; CYTOCHROME P450 1A1; DIOXIN; ESTROGEN RECEPTOR; FLAME RETARDANT; GROWTH FACTOR; LIGAND; POLYCHLORINATED BIPHENYL DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON; RETINOIC ACID; TERATOGENIC AGENT; XENOBIOTIC AGENT;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; COMBUSTION; DNA ADDUCT; EMBRYO DEVELOPMENT; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME INDUCTION; FETOPLACENTAL UNIT; FETUS DEATH; HEAD CIRCUMFERENCE; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; INCINERATION; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; NONHUMAN; PLACENTA; PREGNANCY COMPLICATION; PREMATURITY; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR UPREGULATION; REPRODUCTION; SIGNAL TRANSDUCTION; SMOKING; SOLUTIO PLACENTAE; SOOT; TRANSCRIPTION REGULATION; UPREGULATION; XENOBIOTIC METABOLISM;

EID: 79955629014     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795470994     Document Type: Article

References (188)

1. Myllynen, P.; Pasanen, M.; Pelkonen, O. Human placenta: a human organ for developmental toxicology research and biomonitoring. Placenta, 2005, 26(5), 361-371.
2. Myllynen, P.; Pasanen, M.; Vähäkangas, K. The fate and effects of xenobiotics in human placenta. Expert Opin. Drug Metab. Toxicol., 2007, 3(3), 331-346.
3. Syme, M. R.; Paxton, J. W.; Keelan, J. A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet., 2004, 43(8), 487-514.
4. Pasqualini, J. R. Enzymes involved in the formation and transformation of steroid hormones in the fetal and placental compartments. J. Steroid Biochem. Mol. Biol., 2005, 97(5), 401-415.
5. Desforges, M.; Sibley, C. P. Placental nutrient supply and fetal growth. Int. J. Dev. Biol., 2010, 54(2-3), 377-390.
6. Pavek, P.; Ceckova, M.; Staud, F. Variation of drug kinetics in pregnancy. Curr. Drug Metab., 2009, 10(5), 520-529.
7. Burton, P. J.; Waddell, B. J. Dual function of 11betahydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol. Reprod., 1999, 60(2), 234-240.
8. Hasler, J. A. Pharmacogenetics of cytochromes P450. Mol. Aspects Med., 1999, 20(1-2), 12-24, 25-137.
9. Anzenbacher, P.; Anzenbacherová, E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life Sci., 2001, 58(5-6), 737-747.
10. Lewis, D. F.; Watson, E.; Lake, B. G. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat. Res., 1998, 410(3), 245-270.
11. Guengerich, F. P. Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J. Biochem. Mol. Toxicol., 2007, 21(4), 163-168.
12. Neve, E. P.; Ingelman-Sundberg, M. Intracellular transport and localization of microsomal cytochrome P450. Anal. Bioanal. Chem., 2008, 392(6), 1075-1084.
13. Pavek, P.; Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab., 2008, 9(2), 129-143.
14. Androutsopoulos, V. P.; Tsatsakis, A. M.; Spandidos, D. A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer, 2009, 9, 187.
15. Hankinson, O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 307-340.
16. Stevens, E. A.; Mezrich, J. D.; Bradfield, C. A. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology, 2009, 127(3), 299-311.
17. Corchero, J.; Pimprale, S.; Kimura, S.; Gonzalez, F. J. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics, 2001, 11(1), 1-6.
18. Monostory, K.; Pascussi, J. M.; Kóbori, L.; Dvorak, Z. Hormonal regulation of CYP1A expression. Drug Metab. Rev., 2009, 41(4), 547-572.
19. Don, M. J.; Lewis, D. F.; Wang, S. Y.; Tsai, M. W.; Ueng, Y. F. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorg. Med. Chem. Lett., 2003, 13(15), 2535-2538.
20. Nebert, D. W.; Dalton, T. P.; Okey, A. B.; Gonzalez, F. J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem., 2004, 279(23), 23847-23850.
21. Ikeya, K.; Jaiswal, A. K.; Owens, R. A.; Jones, J. E.; Nebert, D. W.; Kimura, S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol. Endocrinol., 1989, 3(9), 1399-1408.
22. Doshi, M.; Marcus, C.; Bejjani, B. A.; Edward, D. P. Immunolocalization of CYP1B1 in normal, human, fetal and adult eyes. Exp. Eye Res., 2006, 82(1), 24-32.
23. Dragin, N.; Dalton, T. P.; Miller, M. L.; Shertzer, H. G.; Nebert, D. W. For dioxin-induced birth defects, mouse or human CYP1A2 in maternal liver protects whereas mouse CYP1A1 and CYP1B1 are inconsequential. J. Biol. Chem., 2006, 281(27), 18591-18600.
24. Ma, Q.; Lu, A. Y. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos., 2007, 35(7), 1009-1016.
25. Wei, C.; Caccavale, R. J.; Weyand, E. H.; Chen, S.; Iba, M. M. Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung. Cancer Lett., 2002, 178(1), 25-36.
26. McFadyen, M. C.; Rooney, P. H.; Melvin, W. T.; Murray, G. I. Quantitative analysis of the Ah receptor/cytochrome P450 CYP1B1/CYP1A1 signalling pathway. Biochem. Pharmacol., 2003, 65(10), 1663-1674.
27. Coumoul, X.; Diry, M.; Robillot, C.; Barouki, R. Differential regulation of cytochrome P450 1A1 and 1B1 by a combination of dioxin and pesticides in the breast tumor cell line MCF-7. Cancer Res., 2001, 61(10), 3942-3948.
28. Husbeck, B.; Powis, G. The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells. Carcinogenesis, 2002, 23(10), 1625-1630.
29. Yoshinari, K.; Yoda, N.; Toriyabe, T.; Yamazoe, Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. Biochem. Pharmacol., 2010, 79(2), 261-269.
30. Westerink, W. M.; Stevenson, J. C.; Schoonen, W. G. Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch. Toxicol., 2008, 82(12), 909-921.
31. Fujii-Kuriyama, Y.; Kawajiri, K. Molecular mechanisms of the physiological functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to environmental stimuli. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 2010, 86(1), 40-53.
32. Galijatovic, A.; Beaton, D.; Nguyen, N.; Chen, S.; Bonzo, J.; Johnson, R.; Maeda, S.; Karin, M.; Guengerich, F. P.; Tukey, R. H. The human CYP1A1 gene is regulated in a developmental and tissue-specific fashion in transgenic mice. J. Biol. Chem., 2004, 279(23), 23969-23976.
33. Riddick, D. S.; Huang, Y.; Harper, P. A.; Okey, A. B. 2,3,7,8-Tetrachlorodibenzo-p-dioxin versus 3-methylcholanthrene: comparative studies of Ah receptor binding, transformation, and induction of CYP1A1. J. Biol. Chem., 1994, 269(16), 12118-12128.
34. Yoshinari, K.; Ueda, R.; Kusano, K.; Yoshimura, T.; Nagata, K.; Yamazoe, Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem. Pharmacol., 2008, 76(1), 139-145.
35. Werlinder, V.; Backlund, M.; Zhukov, A.; Ingelman-Sundberg, M. Transcriptional and post-translational regulation of CYP1A1 by primaquine. J. Pharmacol. Exp. Ther., 2001, 297(1), 206-214.
36. Curi-Pedrosa, R.; Daujat, M.; Pichard, L.; Ourlin, J. C.; Clair, P.; Gervot, L.; Lesca, P.; Domergue, J.; Joyeux, H.; Fourtanier, G.; et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther., 1994, 269(1), 384-392.
37. Sugihara, K.; Kitamura, S.; Yamada, T.; Okayama, T.; Ohta, S.; Yamashita, K.; Yasuda, M.; Fujii-Kuriyama, Y.; Saeki, K.; Matsui, S.; Matsuda, T. Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo. Biochem. Biophys. Res. Commun., 2004, 318(2), 571-578.
38. Shimada, T.; Fujii-Kuriyama, Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci., 2004, 95(1), 1-6.
39. Schwarz, D.; Kisselev, P.; Cascorbi, I.; Schunck, W. H.; Roots, I. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis, 2001, 22(3), 453-459.
40. Jernström, B.; Gräslund, A. Covalent binding of benzo[a]pyrene 7,8-dihydrodiol 9,10-epoxides to DNA: molecular structures, induced mutations and biological consequences. Biophys. Chem., 1994, 49(3), 185-199.
41. Thomas, R. D.; Green, M. R.; Wilson, C.; Weckle, A. L.; Duanmu, Z.; Kocarek, T. A.; Runge-Morris, M. Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells. Chem. Biol. Interact., 2006, 160(3), 204-216.
42. Crofts, F. G.; Sutter, T. R.; Strickland, P. T. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cyto chrome P4501A1, P4501A2 and P4501B1. Carcinogenesis, 1998, 19(11), 1969-1973.
43. Fujita, K.; Kamataki, T. Predicting the mutagenicity of tobaccorelated N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ. Mol. Mutagen., 2001, 38(4), 339-346.
44. Arranz, N.; Haza, A. I.; Garcia, A.; Rafter, J.; Morales, P. Protective effect of vitamin C towards N-nitrosamine-induced DNA damage in the single-cell gel electrophoresis (SCGE)/HepG2 assay. Toxicol. In Vitro, 2007, 21(7), 1311-1317.
45. Goasduff, T.; Dreano, Y.; Guillois, B.; Menez, J. F.; Berthou, F. Induction of liver and kidney CYP1A1/1A2 by caffeine in rat. Biochem. Pharmacol., 1996, 52(12), 1915-1919.
46. Balat, O.; Balat, A.; Ugur, M. G.; Pence, S. The effect of smoking and caffeine on the fetus and placenta in pregnancy. Clin. Exp. Obstet. Gynecol., 2003, 30(1), 57-59.
47. Caldwell, M. D.; Berg, R. L.; Zhang, K. Q.; Glurich, I.; Schmelzer, J. R.; Yale, S. H.; Vidaillet, H. J.; Burmester, J. K. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res., 2007, 5(1), 8-16.
48. Kaminsky, L. S.; Zhang, Z. Y. Human P450 metabolism of warfarin. Pharmacol. Ther., 1997, 73(1), 67-74.
49. Zhang, Z.; Fasco, M. J.; Huang, Z.; Guengerich, F. P.; Kaminsky, L. S. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab. Dispos., 1995, 23(12), 1339-1346.
50. Mehndiratta, S.; Suneja, A.; Gupta, B.; Bhatt, S. Fetotoxicity of warfarin anticoagulation. Arch. Gynecol. Obstet., 2010, 282(3), 335-337
51. Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S. D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res., 2007, 13(12), 3731-3737.
52. Abellar, R. G.; Pepperell, J. R.; Greco, D.; Gundogan, F.; Kostadinov, S.; Schwartz, J.; Tantravahi, U.; De Paepe, M. E. Effects of chemotherapy during pregnancy on the placenta. Pediatr. Dev. Pathol., 2009, 12(1), 35-41.
53. Granvil, C. P.; Krausz, K. W.; Gelboin, H. V.; Idle, J. R.; Gonzalez, F. J. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J. Pharmacol. Exp. Ther., 2002, 301(3), 1025-1032.
54. Schwarz, D.; Kisselev, P.; Ericksen, S. S.; Szklarz, G. D.; Chernogolov, A.; Honeck, H.; Schunck, W. H.; Roots, I. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem. Pharmacol., 2004, 67(8), 1445-1457.
55. Murphy, V. E.; Smith, R.; Giles, W. B.; Clifton, V. L. Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr. Rev., 2006, 27(2), 141-169.
56. Rama, S.; Petrusz, P.; Rao, A. J. Hormonal regulation of human trophoblast differentiation: a possible role for 17beta-estradiol and GnRH. Mol. Cell. Endocrinol., 2004, 218(1-2), 79-94.
57. Samson, M.; Labrie, F.; Luu-The, V. Specific estradiol biosynthetic pathway in choriocarcinoma (JEG-3) cell line. J. Steroid Biochem. Mol. Biol., 2009, 116(3-5), 154-159.
58. Zhu, B. T.; Cai, M. X.; Spink, D. C.; Hussain, M. M.; Busch, C. M.; Ranzini, A. C.; Lai, Y. L.; Lambert, G. H.; Thomas, P. E.; Conney, A. H. Stimulatory effect of cigarette smoking on the 15 alpha-hydroxylation of estradiol by human term placenta. Clin. Pharmacol. Ther., 2002, 71(5), 311-324.
59. Zhu, B. T.; Lee, A. J. NADPH-dependent metabolism of 17betaestradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. Steroids, 2005, 70(4), 225-244.
60. Cavalieri, E.; Frenkel, K.; Liehr, J. G.; Rogan, E.; Roy, D. Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J. Natl. Cancer Inst. Monogr., 2000, 27, 75-93.
61. Zhang, Q. Y.; Dunbar, D.; Kaminsky, L. Human cytochrome P-450 metabolism of retinals to retinoic acids. Drug Metab. Dispos., 2000, 28(3), 292-297.
62. Shimada, T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab. Pharmacokinet., 2006, 21(4), 257-276.
63. Shimada, T.; Murayama, N.; Okada, K.; Funae, Y.; Yamazaki, H.; Guengerich, F. P. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. Chem. Res. Toxicol., 2007, 20(3), 489-496.
64. Shimada, T.; El-Bayoumy, K.; Upadhyaya, P.; Sutter, T. R.; Guengerich, F. P.; Yamazaki, H. Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. Cancer Res., 1997, 57(21), 4757-4764.
65. Chun, Y. J.; Ryu, S. Y.; Jeong, T. C.; Kim, M. Y. Mechanismbased inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab. Dispos., 2001, 29(4 Pt 1), 389-393.
66. Chun, Y. J.; Kim, M. Y.; Guengerich, F. P. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun., 1999, 262(1), 20-24.
67. Lautraite, S.; Musonda, A. C.; Doehmer, J.; Edwards, G. O.; Chipman, J. K. Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1. Mutagenesis, 2002, 17(1), 45-53.
68. Zhai, S.; Dai, R.; Friedman, F. K.; Vestal, R. E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos., 1998, 26(10), 989-992.
69. Shimada, T.; Guengerich, F. P. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. Chem. Res. Toxicol., 2006, 19(2), 288-294.
70. Schwarz, D.; Kisselev, P.; Chernogolov, A.; Schunck, W. H.; Roots, I. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem. Biophys. Res. Commun., 2005, 336(3), 779-783.
71. Zhou, S. F.; Liu, J. P.; Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 2009, 41(2), 89-295.
72. Landi, M. T.; Bertazzi, P. A.; Shields, P. G.; Clark, G.; Lucier, G. W.; Garte, S. J.; Cosma, G.; Caporaso, N. E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics, 1994, 4(5), 242-246.
73. Suh, Y. J.; Kim, B. M.; Park, B. H.; Park, H.; Kim, Y. J.; Kim, H.; Hong, Y. C.; Ha, E. H. Cytochrome P450IA1 polymorphisms along with PM(10) exposure contribute to the risk of birth weight reduction. Reprod. Toxicol., 2007, 24(3-4), 281-288.
74. Wang, X.; Zuckerman, B.; Pearson, C.; Kaufman, G.; Chen, C.; Wang, G.; Niu, T.; Wise, P. H.; Bauchner, H.; Xu, X. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA, 2002, 287(2), 195-202.
75. Sasaki, S.; Kondo, T.; Sata, F.; Saijo, Y.; Katoh, S.; Nakajima, S.; Ishizuka, M.; Fujita, S.; Kishi, R. Maternal smoking during pregnancy and genetic polymorphisms in the Ah receptor, CYP1A1 and GSTM1 affect infant birth size in Japanese subjects. Mol. Hum. Reprod., 2006, 12(2), 77-83.
76. Chen, D.; Hu, Y.; Yang, F.; Li, Z.; Wu, B.; Fang, Z.; Li, J.; Wang, L. Cytochrome P450 gene polymorphisms and risk of low birth weight. Genet. Epidemiol., 2005, 28(4), 368-375.
77. Wu, T.; Hu, Y.; Chen, C.; Yang, F.; Li, Z.; Fang, Z.; Wang, L.; Chen, D. Passive smoking, metabolic gene polymorphisms, and infant birth weight in a prospective cohort study of Chinese women. Am. J. Epidemiol., 2007, 166(3), 313-322.
78. Suryanarayana, V.; Deenadayal, M.; Singh, L. Association of CYP1A1 gene polymorphism with recurrent pregnancy loss in the South Indian population. Hum. Reprod., 2004, 19(11), 2648-2652.
79. Saijo, Y.; Sata, F.; Yamada, H.; Suzuki, K.; Sasaki, S.; Kondo, T.; Gong, Y. Y.; Kato, E. H.; Shimada, S.; Morikawa, M.; Minakami, H.; Kishi, R. Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss. Mol. Hum. Reprod., 2004, 10(10), 729-733.
80. Tsai, H. J.; Liu, X.; Mestan, K.; Yu, Y.; Zhang, S.; Fang, Y.; Pearson, C.; Ortiz, K.; Zuckerman, B.; Bauchner, H.; Cerda, S.; Stubblefield, P. G.; Xu, X.; Wang, X. Maternal cigarette smoking, metabolic gene polymorphisms, and preterm delivery: new insights on GxE interactions and pathogenic pathways. Hum. Genet., 2008, 123(4), 359-369.
81. Whyatt, R. M.; Bell, D. A.; Jedrychowski, W.; Santella, R. M.; Garte, S. J.; Cosma, G.; Manchester, D. K.; Young, T. L.; Cooper, T. B.; Ottman, R.; Perera, F. P. Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype. Carcinogenesis, 1998, 19(8), 1389-1392.
82. Whyatt, R. M.; Garte, S. J.; Cosma, G.; Bell, D. A.; Jedrychowski, W.; Wahrendorf, J.; Randall, M. C.; Cooper, T. B.; Ottman, R.; Tang, D.; et al. CYP1A1 messenger RNA levels in placental tissue as a biomarker of environmental exposure. Cancer Epidemiol. Biomarkers Prev., 1995, 4(2), 147-153.
83. Czekaj, P.; Wiaderkiewicz, A.; Florek, E.; Wiaderkiewicz, R. Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta. Arch. Toxicol., 2005, 79(1), 13-24.
84. Hakkola, J.; Pasanen, M.; Hukkanen, J.; Pelkonen, O.; Maenpaa, J.; Edwards, R. J.; Boobis, A. R.; Raunio, H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol., 1996, 51(4), 403-411.
85. Avery, M. L.; Meek, C. E.; Audus, K. L. The presence of inducible cytochrome P450 types 1A1 and 1A2 in the BeWo cell line. Placenta, 2003, 24(1), 45-52.
86. Hakkola, J.; Raunio, H.; Purkunen, R.; Pelkonen, O.; Saarikoski, S.; Cresteil, T.; Pasanen, M. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol., 1996, 52(2), 379-383.
87. Hakkola, J.; Pasanen, M.; Pelkonen, O.; Hukkanen, J.; Evisalmi, S.; Anttila, S.; Rane, A.; Mantyla, M.; Purkunen, R.; Saarikoski, S.; Tooming, M.; Raunio, H. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis, 1997, 18(2), 391-397.
88. Collier, A. C.; Tingle, M. D.; Paxton, J. W.; Mitchell, M. D.; Keelan, J. A. Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum. Reprod., 2002, 17(10), 2564-2572.
89. Sanyal, M. K.; Li, Y. L.; Belanger, K. Metabolism of polynuclear aromatic hydrocarbon in human term placenta influenced by cigarette smoke exposure. Reprod. Toxicol., 1994, 8(5), 411-418.
90. Okey, A. B.; Giannone, J. V.; Smart, W.; Wong, J. M.; Manchester, D. K.; Parker, N. B.; Feeley, M. M.; Grant, D. L.; Gilman, A. Binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin to AH receptor in placentas from normal versus abnormal pregnancy outcomes. Chemosphere, 1997, 34(5-7), 1535-1547.
91. Shiverick, K. T.; Salafia, C. Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Placenta, 1999, 20(4), 265-272.
92. Juchau, M. R. Human placental hydroxylation of 3,4-benzpyrene during early gestation and at term. Toxicol. Appl. Pharmacol., 1971, 18(3), 665-675.
93. Sanyal, M. K.; Li, Y. L.; Biggers, W. J.; Satish, J.; Barnea, E. R. Augmentation of polynuclear aromatic hydrocarbon metabolism of human placental tissues of first-trimester pregnancy by cigarette smoke exposure. Am. J. Obstet. Gynecol., 1993, 168(5), 1587-1597.
94. Bruchova, H.; Vasikova, A.; Merkerova, M.; Milcova, A.; Topinka, J.; Balascak, I.; Pastorkova, A.; Sram, R. J.; Brdicka, R. Effect of Maternal Tobacco Smoke Exposure on the Placental Transcriptome. Placenta, 2010, 31(3), 186-191.
95. Huuskonen, P.; Storvik, M.; Reinisalo, M.; Honkakoski, P.; Rysa, J.; Hakkola, J.; Pasanen, M. Microarray analysis of the global alterations in the gene expression in the placentas from cigarettesmoking mothers. Clin. Pharmacol. Ther., 2008, 83(4), 542-550.
96. Pasanen, M.; Haaparanta, T.; Sundin, M.; Sivonen, P.; Vakakangas, K.; Raunio, H.; Hines, R.; Gustafsson, J. A.; Pelkonen, O. Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent monooxygenase activities. Toxicology, 1990, 62(2), 175-187.
97. Boden, A. G.; Bush, P. G.; Burke, M. D.; Abramovich, D. R.; Aggett, P.; Mayhew, T. M.; Page, K. R. Human placental cytochrome P450 and quinone reductase enzyme induction in relation to maternal smoking. Reprod. Fertil. Dev., 1995, 7(6), 1521-1524.
98. Kaelin, A. C.; Cummings, A. J. A survey of aryl hydrocarbon hydroxylase activity in human placental homogenates. Placenta, 1983, 4 Spec No, 471-478.
99. Sanyal, M. K.; Li, Y. L. Differential metabolism of benzo[alpha] pyrene in vitro by human placental tissues exposed to active maternal cigarette smoke. Birth Defects Res. B Dev. Reprod. Toxicol., 2007, 80(1), 49-56.
100. Lagueux, J.; Pereg, D.; Ayotte, P.; Dewailly, E.; Poirier, G. G. Cytochrome P450 CYP1A1 enzyme activity and DNA adducts in placenta of women environmentally exposed to organochlorines. Environ. Res., 1999, 80(4), 369-382.
101. Gallagher, J. E.; Everson, R. B.; Lewtas, J.; George, M.; Lucier, G. W. Comparison of DNA adduct levels in human placenta from polychlorinated biphenyl exposed women and smokers in which CYP 1A1 levels are similarly elevated. Teratog. Carcinog. Mutagen., 1994, 14(4), 183-192.
102. Lucier, G. W.; Sunahara, G. I.; Wong, T. K. Placental markers of human exposure to polychlorinated dibenzofurans and polychlorinated biphenyls: implications for risk assessment. IARC Sci. Publ., 1990, 104, 55-62.
103. Pereg, D.; Dewailly, E.; Poirier, G. G.; Ayotte, P. Environmental exposure to polychlorinated biphenyls and placental CYP1A1 activity in Inuit women from northern Quebec. Environ. Health Perspect., 2002, 110(6), 607-612.
104. Song, Z.; Pollenz, R. S. Ligand-dependent and independent modulation of aryl hydrocarbon receptor localization, degradation, and gene regulation. Mol. Pharmacol., 2002, 62(4), 806-816.
105. Crews, S. T. Control of cell lineage-specific development and transcription by bHLH-PAS proteins. Genes Dev., 1998, 12(5), 607-620.
106. Elbi, C.; Misteli, T.; Hager, G. L. Recruitment of dioxin receptor to active transcription sites. Mol. Biol. Cell, 2002, 13(6), 2001-2015.
107. Poland, A.; Glover, E.; Kende, A. S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem., 1976, 251(16), 4936-4946.
108. Greenlee, W. F.; Poland, A. Nuclear uptake of 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice. Role of the hepatic cytosol receptor protein. J. Biol. Chem., 1979, 254(19), 9814-9821.
109. Micka, J.; Milatovich, A.; Menon, A.; Grabowski, G. A.; Puga, A.; Nebert, D. W. Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics, 1997, 7(2), 95-101.
110. Johnson, B.; Brooks, B. A.; Heinzmann, C.; Diep, A.; Mohandas, T.; Sparkes, R. S.; Reyes, H.; Hoffman, E.; Lange, E.; Gatti, R. A.; et al. The Ah receptor nuclear translocator gene (ARNT) is located on q21 of human chromosome 1 and on mouse chromosome 3 near Cf-3. Genomics, 1993, 17(3), 592-598.
111. Bennett, P.; Ramsden, D. B.; Williams, A. C. Complete structural characterisation of the human aryl hydrocarbon receptor gene. Clin. Mol. Pathol., 1996, 49(1), M12-M16.
112. Dolwick, K. M.; Schmidt, J. V.; Carver, L. A.; Swanson, H. I.; Bradfield, C. A. Cloning and expression of a human Ah receptor cDNA. Mol. Pharmacol., 1993, 44(5), 911-917.
113. Yamamoto, J.; Ihara, K.; Nakayama, H.; Hikino, S.; Satoh, K.; Kubo, N.; Iida, T.; Fujii, Y.; Hara, T. Characteristic expression of aryl hydrocarbon receptor repressor gene in human tissues: organspecific distribution and variable induction patterns in mononuclear cells. Life Sci., 2004, 74(8), 1039-1049.
114. Manchester, D. K.; Gordon, S. K.; Golas, C. L.; Roberts, E. A.; Okey, A. B. Ah receptor in human placenta: stabilization by molybdate and characterization of binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methylcholanthrene, and benzo(a)pyrene. Cancer Res., 1987, 47(18), 4861-4868.
115. Gasiewicz, T. A.; Henry, E. C.; Collins, L. L. Expression and activity of aryl hydrocarbon receptors in development and cancer. Crit. Rev. Eukaryot. Gene Expr., 2008, 18(4), 279-321.
116. Swedenborg, E.; Pongratz, I. AhR and ARNT modulate ER signaling. Toxicology, 2010, 268(3), 132-138.
117. Puga, A.; Ma, C.; Marlowe, J. L. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem. Pharmacol., 2009, 77(4), 713-722.
118. Reisz-Porszasz, S.; Probst, M. R.; Fukunaga, B. N.; Hankinson, O. Identification of functional domains of the aryl hydrocarbon receptor nuclear translocator protein (ARNT). Mol. Cell. Biol., 1994, 14(9), 6075-6086.
119. Fukunaga, B. N.; Probst, M. R.; Reisz-Porszasz, S.; Hankinson, O. Identification of functional domains of the aryl hydrocarbon receptor. J. Biol. Chem., 1995, 270(49), 29270-29278.
120. Coumailleau, P.; Poellinger, L.; Gustafsson, J. A.; Whitelaw, M. L. Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity. J. Biol. Chem., 1995, 270(42), 25291-25300.
121. Ma, Q.; Whitlock, J. P., Jr. A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Biol. Chem., 1997, 272(14), 8878-8884.
122. Carver, L. A.; LaPres, J. J.; Jain, S.; Dunham, E. E.; Bradfield, C. A. Characterization of the Ah receptor-associated protein, ARA9. J. Biol. Chem., 1998, 273(50), 33580-33587.
123. Meyer, B. K.; Pray-Grant, M. G.; Vanden Heuvel, J. P.; Perdew, G. H. Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol. Cell. Biol., 1998, 18(2), 978-988.
124. Lees, M. J.; Whitelaw, M. L. Multiple roles of ligand in transforming the dioxin receptor to an active basic helix-loop-helix/PAS transcription factor complex with the nuclear protein Arnt. Mol. Cell. Biol., 1999, 19(8), 5811-5822.
125. Fujii-Kuriyama, Y.; Mimura, J. Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. Biochem. Biophys. Res. Commun., 2005, 338(1), 311-317.
126. Safe, S. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol. Lett., 2001, 120(1-3), 1-7.
127. Ishimura, R.; Kawakami, T.; Ohsako, S.; Tohyama, C. Dioxininduced toxicity on vascular remodeling of the placenta. Biochem. Pharmacol., 2009, 77(4), 660-669.
128. Mimura, J.; Fujii-Kuriyama, Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta, 2003, 1619(3), 263-268.
129. Tirona, R. G.; Kim, R. B. Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci., 2005, 94(6), 1169-1186.
130. Pollenz, R. S. The mechanism of AH receptor protein downregulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem. Biol. Interact., 2002, 141(1-2), 41-61.
131. Pollenz, R. S. The aryl-hydrocarbon receptor, but not the arylhydrocarbon receptor nuclear translocator protein, is rapidly depleted in hepatic and nonhepatic culture cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol. Pharmacol., 1996, 49(3), 391-398.
132. Davarinos, N. A.; Pollenz, R. S. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export. J. Biol. Chem., 1999, 274(40), 28708-28715.
133. Fernandez-Salguero, P.; Pineau, T.; Hilbert, D. M.; McPhail, T.; Lee, S. S.; Kimura, S.; Nebert, D. W.; Rudikoff, S.; Ward, J. M.; Gonzalez, F. J. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science, 1995, 268(5211), 722-726.
134. Schmidt, J. V.; Su, G. H.; Reddy, J. K.; Simon, M. C.; Bradfield, C. A. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc. Natl. Acad. Sci. U S A, 1996, 93(13), 6731-6736.
135. Mimura, J.; Yamashita, K.; Nakamura, K.; Morita, M.; Takagi, T. N.; Nakao, K.; Ema, M.; Sogawa, K.; Yasuda, M.; Katsuki, M.; Fujii-Kuriyama, Y. Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells, 1997, 2(10), 645-654.
136. Lahvis, G. P.; Bradfield, C. A. Ahr null alleles: distinctive or different?. Biochem. Pharmacol., 1998, 56(7), 781-787.
137. Lahvis, G. P.; Lindell, S. L.; Thomas, R. S.; McCuskey, R. S.; Murphy, C.; Glover, E.; Bentz, M.; Southard, J.; Bradfield, C. A. Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc. Natl. Acad. Sci. USA, 2000, 97(19), 10442-10447.
138. Gonzalez, F. J.; Fernandez-Salguero, P. The aryl hydrocarbon receptor: studies using the AHR-null mice. Drug Metab. Dispos., 1998, 26(12), 1194-1198.
139. Fernandez-Salguero, P. M.; Ward, J. M.; Sundberg, J. P.; Gonzalez, F. J. Lesions of aryl-hydrocarbon receptor-deficient mice. Vet. Pathol., 1997, 34(6), 605-614.
140. Puga, A.; Marlowe, J.; Barnes, S.; Chang, C. Y.; Maier, A.; Tan, Z.; Kerzee, J. K.; Chang, X.; Strobeck, M.; Knudsen, E. S. Role of the aryl hydrocarbon receptor in cell cycle regulation. Toxicology, 2002, 181-182, 171-177.
141. Elizondo, G.; Fernandez-Salguero, P.; Sheikh, M. S.; Kim, G. Y.; Fornace, A. J.; Lee, K. S.; Gonzalez, F. J. Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol. Pharmacol., 2000, 57(5), 1056-1063.
142. Ma, Q.; Whitlock, J. P., Jr. The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol. Cell. Biol., 1996, 16(5), 2144-2150.
143. Caruso, J. A.; Mathieu, P. A.; Joiakim, A.; Zhang, H.; Reiners, J. J. Jr., Aryl hydrocarbon receptor modulation of tumor necrosis factoralpha-induced apoptosis and lysosomal disruption in a hepatoma model that is caspase-8-independent. J. Biol. Chem., 2006, 281(16), 10954-10967.
144. Wu, R.; Zhang, L.; Hoagland, M. S.; Swanson, H. I. Lack of the aryl hydrocarbon receptor leads to impaired activation of AKT/protein kinase B and enhanced sensitivity to apoptosis induced via the intrinsic pathway. J. Pharmacol. Exp. Ther., 2007, 320(1), 448-457.
145. Denison, M. S.; Pandini, A.; Nagy, S. R.; Baldwin, E. P.; Bonati, L. Ligand binding and activation of the Ah receptor. Chem. Biol. Interact., 2002, 141(1-2), 3-24.
146. Nguyen, L. P.; Bradfield, C. A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol., 2008, 21(1), 102-116.
147. Van der Heiden, E.; Bechoux, N.; Muller, M.; Sergent, T.; Schneider, Y. J.; Larondelle, Y.; Maghuin-Rogister, G.; Scippo, M. L. Food flavonoid aryl hydrocarbon receptor-mediated agonistic/ antagonistic/synergic activities in human and rat reporter gene assays. Anal. Chim. Acta, 2009, 637(1-2), 337-345.
148. Amakura, Y.; Tsutsumi, T.; Nakamura, M.; Kitagawa, H.; Fujino, J.; Sasaki, K.; Toyoda, M.; Yoshida, T.; Maitani, T. Activation of the aryl hydrocarbon receptor by some vegetable constituents determined using in vitro reporter gene assay. Biol. Pharm. Bull., 2003, 26(4), 532-539.
149. Wattenberg, L. W.; Loub, W. D. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res., 1978, 38(5), 1410-1413.
150. Adachi, J.; Mori, Y.; Matsui, S.; Takigami, H.; Fujino, J.; Kitagawa, H.; Miller, C. A., 3rd; Kato, T.; Saeki, K.; Matsuda, T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem., 2001, 276(34), 31475-31478.
151. Nishiumi, S.; Yamamoto, N.; Kodoi, R.; Fukuda, I.; Yoshida, K.; Ashida, H. Antagonistic and agonistic effects of indigoids on the transformation of an aryl hydrocarbon receptor. Arch. Biochem. Biophys., 2008, 470(2), 187-199.
152. Guengerich, F.P.; Martin, M. V.; McCormick, W. A.; Nguyen, L. P.; Glover, E.; Bradfield, C. A. Aryl hydrocarbon receptor response to indigoids in vitro and in vivo. Arch. Biochem. Biophys., 2004, 423(2), 309-316.
153. Jinno, A.; Maruyama, Y.; Ishizuka, M.; Kazusaka, A.; Nakamura, A.; Fujita, S. Induction of cytochrome P450-1A by the equine estrogen equilenin, a new endogenous aryl hydrocarbon receptor ligand. J. Steroid. Biochem. Mol. Biol., 2006, 98(1), 48-55.
154. Sinal, C. J.; Bend, J. R. Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells. Mol. Pharmacol., 1997, 52(4), 590-599.
155. Phelan, D.; Winter, G. M.; Rogers, W. J.; Lam, J. C.; Denison, M. S. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch. Biochem. Biophys., 1998, 357(1), 155-163.
156. Schaldach, C. M.; Riby, J.; Bjeldanes, L. F. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry, 1999, 38(23), 7594-7600.
157. Seidel, S. D.; Winters, G. M.; Rogers, W. J.; Ziccardi, M. H.; Li, V.; Keser, B.; Denison, M. S. Activation of the Ah receptor signaling pathway by prostaglandins. J. Biochem. Mol. Toxicol., 2001, 15(4), 187-196.
158. Heath-Pagliuso, S.; Rogers, W. J.; Tullis, K.; Seidel, S. D.; Cenijn, P. H.; Brouwer, A.; Denison, M. S. Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry, 1998, 37(33), 11508-11515.
159. Miller, C. A., 3rd. Expression of the human aryl hydrocarbon receptor complex in yeast. Activation of transcription by indole compounds. J. Biol. Chem., 1997, 272(52), 32824-32829.
160. Wei, Y. D.; Helleberg, H.; Rannug, U.; Rannug, A. Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole. Chem. Biol. Interact., 1998, 110(1-2), 39-55.
161. Katiyar, S. K.; Matsui, M. S.; Mukhtar, H. Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. J. Invest. Dermatol., 2000, 114(2), 328-333.
162. Diani-Moore, S.; Labitzke, E.; Brown, R.; Garvin, A.; Wong, L.; Rifkind, A. B. Sunlight generates multiple tryptophan photoproducts eliciting high efficacy CYP1A induction in chick hepatocytes and in vivo. Toxicol. Sci., 2006, 90(1), 96-110.
163. Haritash, A. K.; Kaushik, C. P. Biodegradation aspects of polycyclic aromatic hydrocarbons (PAHs): a review. J. Hazard. Mater., 2009, 169(1-3), 1-15.
164. La Rocca, C.; Mantovani, A. From environment to food: the case of PCB. Ann. Ist. Super. Sanita, 2006, 42(4), 410-416.
165. Safe, S.; Bandiera, S.; Sawyer, T.; Robertson, L.; Safe, L.; Parkinson, A.; Thomas, P. E.; Ryan, D. E.; Reik, L. M.; Levin, W.; et al. PCBs: structure-function relationships and mechanism of action. Environ. Health Perspect., 1985, 60, 47-56.
166. Vickers, A. E.; Sloop, T. C.; Lucier, G. W. Mechanism of action of toxic halogenated aromatics. Environ. Health Perspect., 1985, 59, 121-128.
167. Hayes, K. R.; Zastrow, G. M.; Nukaya, M.; Pande, K.; Glover, E.; Maufort, J. P.; Liss, A. L.; Liu, Y.; Moran, S. M.; Vollrath, A. L.; Bradfield, C. A. Hepatic transcriptional networks induced by exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Chem. Res. Toxicol., 2007, 20(11), 1573-1581.
168. Kawajiri, K.; Watanabe, J.; Eguchi, H.; Nakachi, K.; Kiyohara, C.; Hayashi, S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics, 1995, 5(3), 151-158.
169. Harper, P. A.; Wong, J. Y.; Lam, M. S.; Okey, A. B. Polymorphisms in the human AH receptor. Chem. Biol. Interact., 2002, 141(1-2), 161-187.
170. Connor, K. T.; Aylward, L. L. Human response to dioxin: aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR. J. Toxicol. Environ. Health B Crit. Rev., 2006, 9(2), 147-171.
171. Cao, H.; Hegele, R. A. Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. J. Hum. Genet., 2000, 45(2), 92-93.
172. Watanabe, T.; Imoto, I.; Kosugi, Y.; Fukuda, Y.; Mimura, J.; Fujii, Y.; Isaka, K.; Takayama, M.; Sato, A.; Inazawa, J. Human arylhydrocarbon receptor repressor (AHRR) gene: genomic structure and analysis of polymorphism in endometriosis. J. Hum. Genet., 2001, 46(6), 342-346.
173. Fujita, H.; Kosaki, R.; Yoshihashi, H.; Ogata, T.; Tomita, M.; Hasegawa, T.; Takahashi, T.; Matsuo, N.; Kosaki, K. Characterization of the aryl hydrocarbon receptor repressor gene and association of its Pro185Ala polymorphism with micropenis. Teratology, 2002, 65(1), 10-18.
174. Carver, L. A.; Hogenesch, J. B.; Bradfield, C. A. Tissue specific expression of the rat Ah-receptor and ARNT mRNAs. Nucleic Acids Res., 1994, 22(15), 3038-3044.
175. Ietta, F.; Wu, Y.; Winter, J.; Xu, J.; Wang, J.; Post, M.; Caniggia, I. Dynamic HIF1A regulation during human placental development. Biol. Reprod., 2006, 75(1), 112-121.
176. Wang, H.; Wu, X.; Hudkins, K.; Mikheev, A.; Zhang, H.; Gupta, A.; Unadkat, J. D.; Mao, Q. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am. J. Physiol. Endocrinol. Metab., 2006, 291(6), E1295-E1304.
177. Kawakami, T.; Ishimura, R.; Nohara, K.; Takeda, K.; Tohyama, C.; Ohsako, S. Differential susceptibilities of Holtzman and Sprague-Dawley rats to fetal death and placental dysfunction induced by 2,3,7,8-teterachlorodibenzo-p-dioxin (TCDD) despite the identical primary structure of the aryl hydrocarbon receptor. Toxicol. Appl. Pharmacol., 2006, 212(3), 224-236.
178. Li, W.; Donat, S.; Dohr, O.; Unfried, K.; Abel, J. Ah receptor in different tissues of C57BL/6J and DBA/2J mice: use of competitive polymerase chain reaction to measure Ah-receptor mRNA expression. Arch. Biochem. Biophys., 1994, 315(2), 279-284.
179. Gradin, K.; McGuire, J.; Wenger, R. H.; Kvietikova, I.; Fhitelaw, M. L.; Toftgard, R.; Tora, L.; Gassmann, M.; Poellinger, L. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol. Cell. Biol., 1996, 16(10), 5221-5231.
180. Tian, Y. Ah receptor and NF-kappaB interplay on the stage of epigenome. Biochem. Pharmacol., 2009, 77(4), 670-680.
181. Elferink, C. J.; Ge, N. L.; Levine, A. Maximal aryl hydrocarbon receptor activity depends on an interaction with the retinoblastoma protein. Mol. Pharmacol., 2001, 59(4), 664-673.
182. Kewley, R. J.; Whitelaw, M. L.; Chapman-Smith, A. The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int. J. Biochem. Cell Biol., 2004, 36(2), 189-204.
183. Nie, M.; Blankenship, A. L.; Giesy, J. P. Interactions between aryl hydrocarbon receptor (AhR) and hypoxia signaling pathways. Environ. Toxicol. Pharmacol., 2001, 10(1-2), 17-27.
184. Kobayashi, A.; Numayama-Tsuruta, K.; Sogawa, K.; Fujii-Kuriyama, Y. CBP/p300 functions as a possible transcriptional coactivator of Ah receptor nuclear translocator (Arnt). J. Biochem., 1997, 122(4), 703-710.
185. Kallio, P. J.; Okamoto, K.; O'Brien, S.; Carrero, P.; Makino, Y.; Tanaka, H.; Poellinger, L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J., 1998, 17(22), 6573-6586.
186. Ohtake, F.; Fujii-Kuriyama, Y.; Kato, S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem. Pharmacol., 2009, 77(4), 474-484.
187. Ruegg, J.; Swedenborg, E.; Wahlstrom, D.; Escande, A.; Balaguer, P.; Pettersson, K.; Pongratz, I. The transcription factor aryl hydrocarbon receptor nuclear translocator functions as an estrogen receptor beta-selective coactivator, and its recruitment to alternative pathways mediates antiestrogenic effects of dioxin. Mol. Endocrinol., 2008, 22(2), 304-316.
188. Shipley, J. M.; Waxman, D. J. Aryl hydrocarbon receptorindependent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene. Toxicol. Appl. Pharmacol., 2006, 213(2), 87-97.